arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

TANDEM DIABETES CARE INC

TNDM
$17.92 ▼ -1.12 (-5.88%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
56 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
14
Health
Poor
Bearish
auto_awesome

Analytical Summary

TANDEM DIABETES CARE INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.2B
Dividend Yield —
Revenue Growth 5.8% ↗
Op. Margin -5.4% ↗
ROIC -1.9% ↗
FCF / Share $-0.56 ↘
Trailing P/E —
Price / Book 9.6x
FCF Yield —
Debt / Equity 4.62
info Valuation on last close. End-of-day price, Nov 5, 2026.

56-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$254.56M
↑ +5.8% —
Net Income Profit after all expenses
$-21.17M
↑ +59.6% —
Operating Margin Operating profit as % of sales
-5.4%
↑ +23.2% 11th
FCF / Share Free cash flow per share
$-0.56
↓ -901.0% —
Long-Term Debt Long-term obligations
$602.58M
— +0.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
14
Returns
6
Financial Health ↑
16
Cash Quality ↓
27

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 15 years · 56 quarters